Spotlight On: Looking beyond Plavix for evidence of Lipitor type post expiry strategies
Review Of Strategies To Enhance Outcomes For Patients With Type 2 Diabets
Obesity: Effective Treatment Requires Change in Payers\' Perspective
Roadmap to reimbursement and access
Payers Insights Into Future Oncology Management
AHDB_Payers Collaborate with Providers To Adopt Oncology Pathways, New Care Delivery Models
How Payers View Pfizer\'s Rheumatoid Arthritis Pill
Spotlight On: Delivering payer-value early in the drug development process; the role of FDA AdCom panels
New Treatment For Low Testosterone Protects Fertility
View Points: Could Pfizer\'s tofacitinib beat expectation and gain approval next month as a second-line therapy?
Looking beyond Plavix for evidence of Lipitor-type post-expiry strategies
Analysis: Drug Costs Become Bigger Issue In Cancer Care
Why Pfizers Rheumatoid Arthritis Pill May Not Be A Sure Bet
ASCO 2010: Payer Trends in Oncology Management and Latest Clinical Trial Data
Vbcc Aco Article
First Word Pharma View Points Commercial Prospects In The Obesity Market Physician And Analyst Observations
Pfizer’s Rheumatoid Arthritis Pill Not A Slam Dunk
Payers likely to throw up hurdles to Pfizer\'s new RA drug
Pfizer Tactics To Combat Generic Drugmakers Financial Times Dec 5, 2011
Tofacitinib to Be Positioned After Anti-TNFs, Say Payers Based on FDA Panel Review Reuters